

HALOZYME THERAPEUTICS INC

Form 4

July 17, 2007

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
RAMSAY DAVID A

(Last) (First) (Middle)

**C/O HALOZYME
THERAPEUTICS, INC., 11588
SORRENTO VALLEY ROAD,
SUITE 17**

(Street)

SAN DIEGO, CA 92121

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading
Symbol
**HALOZYME THERAPEUTICS
INC [HALO]**

3. Date of Earliest Transaction
(Month/Day/Year)
07/16/2007

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

____ Director _____ 10% Owner
____X____ Officer (give title _____ Other (specify
below) below)
Secretary, CFO

6. Individual or Joint/Group Filing(Check
Applicable Line)

____X____ Form filed by One Reporting Person
____ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/16/2007		S ⁽¹⁾		300	D	\$ 10
							381,110
Common Stock	07/16/2007		S ⁽¹⁾		100	D	\$ 10.01
							381,010
Common Stock	07/16/2007		S ⁽¹⁾		100	D	\$ 10.02
							380,910
Common Stock	07/16/2007		S ⁽¹⁾		100	D	\$ 9.74
							380,810

Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4

Common Stock	07/16/2007	<u>S</u> (1)	100	D	\$ 9.75	380,710	D
Common Stock	07/16/2007	<u>S</u> (1)	300	D	\$ 9.78	380,410	D
Common Stock	07/16/2007	<u>S</u> (1)	400	D	\$ 9.79	380,010	D
Common Stock	07/16/2007	<u>S</u> (1)	2,000	D	\$ 9.8	378,010	D
Common Stock	07/16/2007	<u>S</u> (1)	400	D	\$ 9.81	377,610	D
Common Stock	07/16/2007	<u>S</u> (1)	100	D	\$ 9.82	377,510	D
Common Stock	07/16/2007	<u>S</u> (1)	100	D	\$ 9.83	377,410	D
Common Stock	07/16/2007	<u>S</u> (1)	500	D	\$ 9.84	376,910	D
Common Stock	07/16/2007	<u>S</u> (1)	200	D	\$ 9.85	376,710	D
Common Stock	07/16/2007	<u>S</u> (1)	300	D	\$ 9.86	376,410	D
Common Stock	07/16/2007	<u>S</u> (1)	300	D	\$ 9.89	376,110	D
Common Stock	07/16/2007	<u>S</u> (1)	300	D	\$ 9.9	375,810	D
Common Stock	07/16/2007	<u>S</u> (1)	471	D	\$ 9.92	375,339	D
Common Stock	07/16/2007	<u>S</u> (1)	400	D	\$ 9.93	374,939	D
Common Stock	07/16/2007	<u>S</u> (1)	300	D	\$ 9.94	374,639	D
Common Stock	07/16/2007	<u>S</u> (1)	500	D	\$ 9.95	374,139	D
Common Stock	07/16/2007	<u>S</u> (1)	400	D	\$ 9.96	373,739	D
Common Stock	07/16/2007	<u>S</u> (1)	1,329	D	\$ 9.97	372,410	D
Common Stock	07/16/2007	<u>S</u> (1)	600	D	\$ 9.98	371,810	D
Common Stock	07/16/2007	<u>S</u> (1)	400	D	\$ 9.99	371,410	D

Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

RAMSAY DAVID A
C/O HALOZYME THERAPEUTICS, INC.
11588 SORRENTO VALLEY ROAD, SUITE 17
SAN DIEGO, CA 92121

Secretary, CFO

Signatures

/s/ David A.
Ramsay

07/17/2007

__Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Shares purchased and sold, as applicable, pursuant to 10b5-1 Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.